Marksans Pharma announced its Q3FY26 quarterly results, delivering strong financial performance with consolidated revenue of ₹754.4 crores and net profit of ₹113.7 crores. The pharmaceutical company's Board of Directors approved these unaudited financial results at their meeting held on February 5, 2026, demonstrating robust operational execution across key global markets.

Q3FY26 Financial Performance

The company reported consolidated revenue of ₹754.4 crores in Q3FY26, representing growth of 10.6% compared to ₹681.8 crores in Q3FY25. Net profit increased by 8.2% to ₹113.7 crores from ₹105.1 crores in the corresponding quarter of the previous year. The strong performance was driven by robust traction in US and UK markets, supported by new product launches and market share gains.

Margin Expansion and Profitability

Marksans Pharma achieved significant margin improvements during Q3FY26. EBITDA margin expanded to 21.3% from 19.1% in Q3FY25, marking an increase of 217 basis points. Gross margin improved to 58.1% from 56.2% year-on-year, reflecting benefits from soft raw material costs, favorable currency movements, and an improving product mix. The company maintained its net margin at 15.1% compared to 15.4% in the previous year.

Geographic Performance Analysis

The US & North America formulation business generated revenues of ₹412.4 crores in Q3FY26, contributing 54.7% to total revenue mix and showing growth of 16.9% year-on-year. UK and Europe operations reported revenues of ₹258.2 crores, representing 34.2% of revenue mix with marginal growth of 0.2%. Australia & New Zealand business achieved strong growth of 30.1% with revenues of ₹61.4 crores, while Rest of World markets contributed ₹22.4 crores.

Investor Conference Call and Corporate Communication

Following the announcement of Q3FY26 results, Marksans Pharma conducted an investor and analyst conference call on February 06, 2026. The company has made the audio recording of this earnings call available on its official website under the earnings call transcripts section. This communication was conducted in compliance with Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory Updates and Corporate Developments

The company's statutory auditors M S K A & Associates have converted from a partnership firm into a limited liability partnership firm, functioning under M S K A & Associates LLP, Chartered Accountants effective January 12, 2026. The auditors provided an unmodified opinion on the quarterly results. Subsequent to Q3FY26, Marksans Pharma incorporated two new wholly owned subsidiaries: Marksans Pharma (Europe) Limited in Ireland on January 16, 2026, and Marksans (Canada) Inc. in Canada on January 22, 2026.

Nine-Month Performance Overview

For 9MFY26, Marksans Pharma reported operating revenue of ₹2,094.8 crores, up 9.4% year-on-year, with EBITDA margin of 19.4% aligning with management guidance. The company generated cash from operations of ₹263.2 crores during the nine-month period and maintained a strong cash balance of ₹824.2 crores. Research and development spending reached ₹62.0 crores, representing 3.0% of consolidated revenue, supporting the company's innovation pipeline and future growth prospects.

Marksans Pharma has announced the establishment of two fully owned subsidiaries in Ireland and Canada, marking a significant step in the company's international expansion strategy. The pharmaceutical company's move to create these subsidiaries demonstrates its commitment to strengthening its global operational footprint.

Strategic International Expansion

The establishment of subsidiaries in both Ireland and Canada represents a strategic initiative to enhance the company's pharmaceutical operations in key international markets. These new entities will operate as fully owned subsidiaries, providing Marksans Pharma with direct control over its operations in these regions.

Market Positioning

The decision to establish operations in Ireland and Canada positions Marksans Pharma to better serve these important pharmaceutical markets. Ireland serves as a strategic gateway to European markets, while Canada represents a significant North American opportunity for the company's pharmaceutical products and services.

Operational Framework

Both subsidiaries will focus on pharmaceutical operations, aligning with Marksans Pharma's core business activities. The fully owned structure of these subsidiaries will enable the company to maintain operational control and implement its business strategies effectively in these new markets.